Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Increased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There have been reports indicating that tumor necrosis factor blockers may exert favorable but transient effects on lipid profile, flow-mediated vasodilation (FMD) of the brachial artery, and common carotid intima-media thickness (ccIMT) in RA. In this study, we assessed the effects of rituximab on FMD, ccIMT, and lipid profile. Five female RA patients received two infusions of 1000 mg rituximab i.v. High-resolution B-mode ultrasound was used to assess brachial FMD and ccIMT. We also determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (Tg) levels. Assessments were performed at baseline, as well as at weeks 2, 6, and 16 after the first infusion. Rituximab (RTX) treatment resulted in a rapid and sustained improvement in FMD. The mean improvement was 30%, 22%, and 81% at weeks 2, 6, and 16, respectively. RTX had little effect on atherosclerosis within this short period of time; however, we observed 10%, 9%, and 2% decreases in ccIMT at weeks 2, 6, and 16, respectively. RTX therapy resulted in 3-11% decrease in TC, as well as 14-35% increase in HDL-C levels. Two infusions of RTX exerted early and sustained favorable effects on endothelial dysfunction, as well as plasma TC and HDL-C levels. RTX may also decrease ccIMT; however, longer follow-up is needed to assess the prolonged effects of RTX on vascular function and lipid profile in RA patients.

Original languageEnglish
Pages (from-to)705-710
Number of pages6
JournalClinical Rheumatology
Volume28
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Carotid Artery Diseases
Rheumatoid Arthritis
Carotid Intima-Media Thickness
Lipids
Vasodilation
Therapeutics
HDL Cholesterol
Brachial Artery
Rituximab
Blood Vessels
Atherosclerosis
Arm
Tumor Necrosis Factor-alpha
Cholesterol
Mortality

Keywords

  • Atherosclerosis
  • Carotid intima-media thickness
  • Endothelial dysfunction
  • Flow-mediated vasodilatation
  • Lipid profile
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{554f6fd5a5d145a7af73c542952d7c97,
title = "Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis",
abstract = "Increased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There have been reports indicating that tumor necrosis factor blockers may exert favorable but transient effects on lipid profile, flow-mediated vasodilation (FMD) of the brachial artery, and common carotid intima-media thickness (ccIMT) in RA. In this study, we assessed the effects of rituximab on FMD, ccIMT, and lipid profile. Five female RA patients received two infusions of 1000 mg rituximab i.v. High-resolution B-mode ultrasound was used to assess brachial FMD and ccIMT. We also determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (Tg) levels. Assessments were performed at baseline, as well as at weeks 2, 6, and 16 after the first infusion. Rituximab (RTX) treatment resulted in a rapid and sustained improvement in FMD. The mean improvement was 30{\%}, 22{\%}, and 81{\%} at weeks 2, 6, and 16, respectively. RTX had little effect on atherosclerosis within this short period of time; however, we observed 10{\%}, 9{\%}, and 2{\%} decreases in ccIMT at weeks 2, 6, and 16, respectively. RTX therapy resulted in 3-11{\%} decrease in TC, as well as 14-35{\%} increase in HDL-C levels. Two infusions of RTX exerted early and sustained favorable effects on endothelial dysfunction, as well as plasma TC and HDL-C levels. RTX may also decrease ccIMT; however, longer follow-up is needed to assess the prolonged effects of RTX on vascular function and lipid profile in RA patients.",
keywords = "Atherosclerosis, Carotid intima-media thickness, Endothelial dysfunction, Flow-mediated vasodilatation, Lipid profile, Rheumatoid arthritis, Rituximab",
author = "G. Kerekes and P. Solt{\'e}sz and H. D{\'e}r and K. Veres and Z. Szab{\'o} and A. V{\'e}gv{\'a}ri and G. Szegedi and Yehuda Shoenfeld and Z. Szekanecz",
year = "2009",
doi = "10.1007/s10067-009-1095-1",
language = "English",
volume = "28",
pages = "705--710",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

AU - Kerekes, G.

AU - Soltész, P.

AU - Dér, H.

AU - Veres, K.

AU - Szabó, Z.

AU - Végvári, A.

AU - Szegedi, G.

AU - Shoenfeld, Yehuda

AU - Szekanecz, Z.

PY - 2009

Y1 - 2009

N2 - Increased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There have been reports indicating that tumor necrosis factor blockers may exert favorable but transient effects on lipid profile, flow-mediated vasodilation (FMD) of the brachial artery, and common carotid intima-media thickness (ccIMT) in RA. In this study, we assessed the effects of rituximab on FMD, ccIMT, and lipid profile. Five female RA patients received two infusions of 1000 mg rituximab i.v. High-resolution B-mode ultrasound was used to assess brachial FMD and ccIMT. We also determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (Tg) levels. Assessments were performed at baseline, as well as at weeks 2, 6, and 16 after the first infusion. Rituximab (RTX) treatment resulted in a rapid and sustained improvement in FMD. The mean improvement was 30%, 22%, and 81% at weeks 2, 6, and 16, respectively. RTX had little effect on atherosclerosis within this short period of time; however, we observed 10%, 9%, and 2% decreases in ccIMT at weeks 2, 6, and 16, respectively. RTX therapy resulted in 3-11% decrease in TC, as well as 14-35% increase in HDL-C levels. Two infusions of RTX exerted early and sustained favorable effects on endothelial dysfunction, as well as plasma TC and HDL-C levels. RTX may also decrease ccIMT; however, longer follow-up is needed to assess the prolonged effects of RTX on vascular function and lipid profile in RA patients.

AB - Increased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There have been reports indicating that tumor necrosis factor blockers may exert favorable but transient effects on lipid profile, flow-mediated vasodilation (FMD) of the brachial artery, and common carotid intima-media thickness (ccIMT) in RA. In this study, we assessed the effects of rituximab on FMD, ccIMT, and lipid profile. Five female RA patients received two infusions of 1000 mg rituximab i.v. High-resolution B-mode ultrasound was used to assess brachial FMD and ccIMT. We also determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (Tg) levels. Assessments were performed at baseline, as well as at weeks 2, 6, and 16 after the first infusion. Rituximab (RTX) treatment resulted in a rapid and sustained improvement in FMD. The mean improvement was 30%, 22%, and 81% at weeks 2, 6, and 16, respectively. RTX had little effect on atherosclerosis within this short period of time; however, we observed 10%, 9%, and 2% decreases in ccIMT at weeks 2, 6, and 16, respectively. RTX therapy resulted in 3-11% decrease in TC, as well as 14-35% increase in HDL-C levels. Two infusions of RTX exerted early and sustained favorable effects on endothelial dysfunction, as well as plasma TC and HDL-C levels. RTX may also decrease ccIMT; however, longer follow-up is needed to assess the prolonged effects of RTX on vascular function and lipid profile in RA patients.

KW - Atherosclerosis

KW - Carotid intima-media thickness

KW - Endothelial dysfunction

KW - Flow-mediated vasodilatation

KW - Lipid profile

KW - Rheumatoid arthritis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=67349230306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349230306&partnerID=8YFLogxK

U2 - 10.1007/s10067-009-1095-1

DO - 10.1007/s10067-009-1095-1

M3 - Article

C2 - 19319624

AN - SCOPUS:67349230306

VL - 28

SP - 705

EP - 710

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 6

ER -